
Tom Dragovich, MD, PhD Office and Other Patient Information
Primary Office
Office 1: Baptist MD Anderson Cancer Center
, Jacksonville, FL 32207
904.202.2754
Tom Dragovich, MD, PhD Biography and Info
Dr. Dragovich is a board-certified medical oncologist who has practiced oncology for over two decades and has a PhD in molecular pharmacology. His area of expertise encompasses all gastrointestinal malignancies, with an emphasis on pancreatic cancer. Dr. Dragovich is passionate about the role of clinical trials in advancing cancer care and is actively involved as a clinical researcher. Prior to joining Baptist MD Anderson, Dr. Dragovich was at the MD Anderson partner cancer center in Arizona. He was one of the founding members and leaders there for over a decade and served as the president of the Arizona Clinical Oncology Society from 2021-2023. His areas of expertise include:
- Pancreatic Cancer
- Esophageal and Gastric Cancer
- Colon and Rectal Cancer
- Cancers of the Liver and Biliary Tract
About Me
In addition to believing in and seeing the success of the MD Anderson model of cancer care, I am excited to join an amazing team of doctors, nurses and leaders at the Baptist MD Anderson Cancer Center. Their enthusiasm and compassion is palpable and contagious. I found Jacksonville to be a "hidden gem" of Florida. It is a vibrant and growing community.
As a physician, I believe in personalized comprehensive cancer care. This approach maximizes the chance of success by integrating cutting-edge therapeutic advances with the specific needs and expectations unique to each patient and their family. I strongly believe most cancers will be conquered in the near future because of recent, unprecedented breakthroughs in science and clinical research. I am grateful for the chance to apply these advances in clinic aiming to provide the best treatment to the right patient and at the right time.
Titles
- Head, Division of Cancer Medicine
Specialties
- Medical Oncology
- Hematology
- Internal Medicine
Boards
- American Board of Internal Medicine (Medical Oncology)
Languages
- English
- Spanish
- Serbo-Croatian
Hospital Affiliation
- Baptist Medical Center Jacksonville
- Baptist Medical Center South
- Baptist Medical Center Clay
Legal Practice Name
- Baptist MD Anderson Cancer Physicians Inc
Ages Treated
- Adult
- Senior
Tom Dragovich, MD, PhD Additional Information
Education & Training
-
Doctor of Medicine - Medical School
School of Medicine University of Belgrade - Belgrade
1982 – 1988
-
Doctor of Philosophy - Post Graduate
University of Illinois at Chicago - Chicago , IL
1989 – 1997
-
Chief Resident - Residency
The University of Chicago B/Louis A Weiss Memorial Hospital - Chicago , IL
1994 – 1997
-
Fellowship
The University of Chicago, Department of Hematology and Oncology - Chicago , IL
1997 – 2000
Publications
-
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. PMID: 39282897
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J
N Engl J Med 2025 Jan 2. 392(1)11-22 doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15.
PMID: 39282897 [PubMed - indexed for MEDLINE]
-
Methods for improving colorectal cancer annotation efficiency for artificial intelligence-observer training. PMID: 38179201
Grudza M, Salinel B, Zeien S, Murphy M, Adkins J, Jensen CT, Bay C, Kodibagkar V, Koo P, Dragovich T, Choti MA, Kundranda M, Syeda-Mahmood T, Wang HZ, Chang J
World J Radiol 2023 Dec 28. 15(12)359-369 doi: 10.4329/wjr.v15.i12.359.
PMID: 38179201 [PubMed]
-
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. PMID: 36715684
Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Kontoyiannis DP, Malek AE, Chaftari AM
Elife 2023 Jan 30. 12 doi: 10.7554/eLife.81127. Epub 2023 Jan 30.
PMID: 36715684 [PubMed - indexed for MEDLINE]
-
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. PMID: 36331676
Pant S, Dragovich T, Lieu C, Jimeno A, Kundranda M, Menter D, Tchaparian E, Chen YC, Kopetz S
Invest New Drugs 2023 Feb. 41(1)25-34 doi: 10.1007/s10637-022-01308-5. Epub 2022 Nov 4.
PMID: 36331676 [PubMed - indexed for MEDLINE]
-
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. PMID: 34753777
Hong DS, Rixe O, Chiu VK, Forde PM, Dragovich T, Lou Y, Nayak-Kapoor A, Leidner R, Atkins JN, Collaku A, Fox FE, Marshall MA, Olszanski AJ
Clin Cancer Res 2022 Feb 1. 28(3)479-488 doi: 10.1158/1078-0432.CCR-21-2781. Epub 2021 Nov 9.
PMID: 34753777 [PubMed - indexed for MEDLINE]
-
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. PMID: 34637336
Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S
J Clin Oncol 2022 Jan 10. 40(2)161-170 doi: 10.1200/JCO.21.01015. Epub 2021 Oct 12.
PMID: 34637336 [PubMed - indexed for MEDLINE]
-
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). PMID: 34149004
Patel JN, Jiang C, Owzar K, Mulkey F, Luzum JA, Mamon HJ, Haller DG, Dragovich T, Alberts SR, Bjarnason G, Willet CG, Niedzwiecki D, Enzinger P, Ratain MJ, Fuchs C, McLeod HL
Pharmacogenet Genomics 2021 Dec 1. 31(9)215-220 doi: 10.1097/FPC.0000000000000442.
PMID: 34149004 [PubMed - indexed for MEDLINE]
-
Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. PMID: 34012639
Puri A, Chang J, Tanner N, Lucente P, Desiongco J, Dragovich T, Naraev B, Kundranda M
J Gastrointest Oncol 2021 Apr. 12(2)455-463 doi: 10.21037/jgo-20-361.
PMID: 34012639 [PubMed]
-
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. PMID: 33758378
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V
Nat Rev Clin Oncol 2021 May. 18(5)320 doi: 10.1038/s41571-021-00503-2.
PMID: 33758378 [PubMed]
-
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. PMID: 33723371
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V
Nat Rev Clin Oncol 2021 May. 18(5)313-319 doi: 10.1038/s41571-021-00487-z. Epub 2021 Mar 15.
PMID: 33723371 [PubMed - indexed for MEDLINE]
-
AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan). PMID: 31786893
Todorovic V, Aapro M, Pavlidis N, Arsovski O, Belkacemi Y, Babovic N, Bidard FC, Bourhafour M, Beslija S, Boussen H, Cetnikovic B, Ceric T, Cicmil N, Crnogorac N, Cuedari E, De Laurentis M, Dragovich T, Durutovic I, Dzamic Z, Dzodic R, Eri Z, Geara F, Khalil A, Kerrou K, Knezevic Usaj S, Kovcin V, Koroveshi D, Kristo Pema A, Kuten A, Lakicevic J, Lukovac N, Markovic I, Markovic M, Mijalkovic N, Miladinova D, Milasevic N, Mustachi G, Ognjenovic D, Pantelic A, Popovic L, Radosavljevic D, Radosevic N, Radulovic S, Ristevski M, Rosic I, Secen N, Sorat M, Stamatovic L, Stefanovski P, Stojkovski I, Tesanovic D, Tomasevic Z, Tomasevic Z, Tsoutsou P, Turkan S, Vasev N, Vasovic S, Vicko F, Vrbanec D, Vukmirovic F, Vrdoljak E, Zaric B, Zambrovski JJ, Cavalli F, Gligorov J
J BUON 2019 Sep-Oct. 24(5)2180-2197.
PMID: 31786893 [PubMed - indexed for MEDLINE]
-
Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. PMID: 30671268
Youssef A, Kasso N, Torloni AS, Stanek M, Dragovich T, Gimbel M, Mahmoud F
Case Rep Hematol 2018. 20182464619 doi: 10.1155/2018/2464619. Epub 2018 Dec 20.
PMID: 30671268 [PubMed]
-
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. PMID: 30410366
Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M, Mahmoud F
Onco Targets Ther 2018. 117095-7107 doi: 10.2147/OTT.S182721. Epub 2018 Oct 17.
PMID: 30410366 [PubMed]
-
Chemotherapy re-challenge response rate in metastatic colorectal cancer. PMID: 30151264
Chambers AE, Frick J, Tanner N, Gerkin R, Kundranda M, Dragovich T
J Gastrointest Oncol 2018 Aug. 9(4)679-686 doi: 10.21037/jgo.2018.04.08.
PMID: 30151264 [PubMed]
-
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. PMID: 29782360
Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H, Mori M, Mattek N, Sanborn RE, Lopez CD
Am J Clin Oncol 2018 Dec. 41(12)1193-1198 doi: 10.1097/COC.0000000000000465.
PMID: 29782360 [PubMed - indexed for MEDLINE]
-
Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer. PMID: 29430233
Swofford BP, Dragovich T
Case Rep Oncol 2017 Sep-Dec. 10(3)1098-1104 doi: 10.1159/000484978. Epub 2017 Dec 11.
PMID: 29430233 [PubMed]
-
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). PMID: 28976791
Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ
J Clin Oncol 2017 Nov 10. 35(32)3671-3677 doi: 10.1200/JCO.2017.74.2130. Epub 2017 Oct 4.
PMID: 28976791 [PubMed - indexed for MEDLINE]
-
Sigmoid Adenocarcinoma with Regional Scrotal Metastasis. PMID: 28626399
Swofford BP, Dragovich T
Case Rep Oncol 2017 May-Aug. 10(2)416-419 doi: 10.1159/000474936. Epub 2017 May 5.
PMID: 28626399 [PubMed]
-
Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. PMID: 26810581
Elquza E, Babiker HM, Howell KJ, Kovoor AI, Brown TD, Patel H, Malangone SA, Borad MJ, Dragovich T
Cancer Invest 2016. 34(2)57-63 doi: 10.3109/07357907.2015.1108426. Epub 2016 Jan 25.
PMID: 26810581 [PubMed - indexed for MEDLINE]
-
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. PMID: 26615328
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT
Lancet 2016 Feb 6. 387(10018)545-557 doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29.
PMID: 26615328 [PubMed - indexed for MEDLINE]
-
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. PMID: 26187510
Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD
Eur J Cancer 2015 Sep. 51(14)1857-64 doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.
PMID: 26187510 [PubMed - indexed for MEDLINE]
-
Anatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future Implications. PMID: 26146615
Chang J, Schomer D, Dragovich T
Biomed Res Int 2015. 2015269641 doi: 10.1155/2015/269641. Epub 2015 Jun 4.
PMID: 26146615 [PubMed - indexed for MEDLINE]
-
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. PMID: 25512461
Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP
J Clin Oncol 2015 May 1. 33(13)1475-81 doi: 10.1200/JCO.2014.55.7504. Epub 2014 Dec 15.
PMID: 25512461 [PubMed - indexed for MEDLINE]
-
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. PMID: 25278310
Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM
Pancreatology 2014 Sep-Oct. 14(5)398-402 doi: 10.1016/j.pan.2014.07.003. Epub 2014 Jul 18.
PMID: 25278310 [PubMed - indexed for MEDLINE]
-
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). PMID: 24939212
Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD
Cancer Chemother Pharmacol 2014 Aug. 74(2)379-87 doi: 10.1007/s00280-014-2499-4. Epub 2014 Jun 18.
PMID: 24939212 [PubMed - indexed for MEDLINE]
-
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. PMID: 23564374
Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D
Cancer Chemother Pharmacol 2013 May. 71(5)1345-55 doi: 10.1007/s00280-013-2134-9. Epub 2013 Apr 6.
PMID: 23564374 [PubMed - indexed for MEDLINE]
-
A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. PMID: 22711542
Baker AF, Adab KN, Raghunand N, Chow H, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T
Invest New Drugs 2013 Jun. 31(3)631-641 doi: 10.1007/s10637-012-9846-2. Epub 2012 Jun 19.
PMID: 22711542 [PubMed - indexed for MEDLINE]
-
Is there a case for personalized therapy of pancreatic cancer? PMID: 22706549
Dragovich T
Clin Adv Hematol Oncol 2012 May. 10(5)344-5.
PMID: 22706549 [PubMed - indexed for MEDLINE]
-
Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. PMID: 21531108
Rajaraman S, Rodriguez JJ, Graff C, Altbach MI, Dragovich T, Sirlin CB, Korn RL, Raghunand N
Magn Reson Imaging 2011 Jun. 29(5)668-82 doi: 10.1016/j.mri.2011.02.012. Epub 2011 Apr 29.
PMID: 21531108 [PubMed - indexed for MEDLINE]
-
Management strategies in pancreatic cancer. PMID: 21411798
Campen CJ, Dragovich T, Baker AF
Am J Health Syst Pharm 2011 Apr 1. 68(7)573-84 doi: 10.2146/ajhp100254.
PMID: 21411798 [PubMed - indexed for MEDLINE]
-
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. PMID: 21325451
Mahadevan D, Plummer R, Squires MS, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H
Ann Oncol 2011 Sep. 22(9)2137-2143 doi: 10.1093/annonc/mdq734. Epub 2011 Feb 16.
PMID: 21325451 [PubMed - indexed for MEDLINE]
-
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. PMID: 20461382
Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD
Cancer Chemother Pharmacol 2011 Mar. 67(3)503-9 doi: 10.1007/s00280-010-1343-8. Epub 2010 May 12.
PMID: 20461382 [PubMed - indexed for MEDLINE]
-
A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. PMID: 19687729
Chiorean EG, Dragovich T, Hamm J, Barrios CH, Gorini CF, Langmuir VK, Kroll S, Jung DT, Tidmarsh GT, Loehrer PJ
Am J Clin Oncol 2010 Apr. 33(2)111-6 doi: 10.1097/COC.0b013e3181979204.
PMID: 19687729 [PubMed - indexed for MEDLINE]
-
Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. PMID: 19636422
Dragovich T, Campen C
J Oncol 2009. 2009804108 doi: 10.1155/2009/804108. Epub 2009 Jul 14.
PMID: 19636422 [PubMed]
-
Discrepancy in the assessment of tumor response in patients with pancreatic cancer: WHO versus RECIST criteria. PMID: 18979550
Ahn SH, Garewal HS, Dragovich T
J BUON 2008 Jul-Sep. 13(3)359-62.
PMID: 18979550 [PubMed - indexed for MEDLINE]
-
Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. PMID: 18469443
Chalasani P, Kurtin S, Dragovich T
JOP 2008 May 8. 9(3)305-8. Epub 2008 May 8.
PMID: 18469443 [PubMed - indexed for MEDLINE]
-
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. PMID: 18467723
Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ
J Clin Oncol 2008 May 10. 26(14)2320-6 doi: 10.1200/JCO.2007.14.0152.
PMID: 18467723 [PubMed - indexed for MEDLINE]
-
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. PMID: 18391600
Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M
Am J Clin Oncol 2008 Apr. 31(2)157-62 doi: 10.1097/COC.0b013e31815878c9.
PMID: 18391600 [PubMed - indexed for MEDLINE]
-
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. PMID: 17661038
Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, Colowick AB, Tidmarsh GF, Loehrer PJ
Cancer Chemother Pharmacol 2008 May. 61(6)1019-26. Epub 2007 Jul 28.
PMID: 17661038 [PubMed - indexed for MEDLINE]
-
The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. PMID: 17545547
Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G
Clin Cancer Res 2007 Jun 1. 13(11)3388-94.
PMID: 17545547 [PubMed - indexed for MEDLINE]
-
Phase I trial of imexon in patients with advanced malignancy. PMID: 17470869
Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R
J Clin Oncol 2007 May 1. 25(13)1779-84.
PMID: 17470869 [PubMed - indexed for MEDLINE]
-
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. PMID: 17404093
Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, Dragovich T
Clin Cancer Res 2007 Apr 1. 13(7)2109-14.
PMID: 17404093 [PubMed - indexed for MEDLINE]
-
Emerging role of target-based therapies for gastrointestinal malignancies. PMID: 17335127
Dragovich T
J BUON 2005 Jan-Mar. 10(1)15-21.
PMID: 17335127 [PubMed]
-
A case of fatal Rosai-Dorfman syndrome in an adult; failure of multiple empiric therapies. PMID: 17309162
Antic N, Ultmann JE, Dragovich T
J BUON 2006 Jul-Sep. 11(3)351-3.
PMID: 17309162 [PubMed - indexed for MEDLINE]
-
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. PMID: 17149608
Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A
Cancer Chemother Pharmacol 2007 Jul. 60(2)295-303. Epub 2006 Dec 6.
PMID: 17149608 [PubMed - indexed for MEDLINE]
-
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. PMID: 17050876
Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL
J Clin Oncol 2006 Oct 20. 24(30)4922-7.
PMID: 17050876 [PubMed - indexed for MEDLINE]
-
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. PMID: 16847673
Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A
Cancer Chemother Pharmacol 2006 Dec. 58(6)759-64. Epub 2006 May 23.
PMID: 16847673 [PubMed - indexed for MEDLINE]
-
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. PMID: 16459166
Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL, Powis G
J Lab Clin Med 2006 Feb. 147(2)83-90.
PMID: 16459166 [PubMed - indexed for MEDLINE]
-
Stability of phosphoprotein as a biological marker of tumor signaling. PMID: 15958615
Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G
Clin Cancer Res 2005 Jun 15. 11(12)4338-40.
PMID: 15958615 [PubMed - indexed for MEDLINE]
-
Signal transduction pathways that regulate cell survival and cell death. PMID: 9916983
Dragovich T, Rudin CM, Thompson CB
Oncogene 1998 Dec 24. 17(25)3207-13.
PMID: 9916983 [PubMed - indexed for MEDLINE]
Additional Publications from Tom Dragovich, MD, PhD (50 Citations)